vs
MESA LABORATORIES INC（MLAB）とVelocity Financial, Inc.（VEL）の財務データ比較。上の社名をクリックして会社を切り替えられます
MESA LABORATORIES INCの直近四半期売上が大きい（$65.1M vs $51.6M、Velocity Financial, Inc.の約1.3倍）。Velocity Financial, Inc.の純利益率が高く（67.3% vs 5.6%、差は61.8%）。Velocity Financial, Inc.の前年同期比売上増加率が高い（32.8% vs 3.6%）。MESA LABORATORIES INCの直近四半期フリーキャッシュフローが多い（$18.0M vs $17.9M）。過去8四半期でVelocity Financial, Inc.の売上複合成長率が高い（32.3% vs 5.1%）
メサラボラトリーズ社は、品質管理、校正、モニタリング向け専門機器及び関連サービスの開発・製造・販売を事業としています。医療、製薬、食品飲料、産業衛生、環境試験分野を中心に、世界中の顧客の規制遵守と運用安全のニーズに応えています。
Velocity Financial, Inc.は米国に本社を置く不動産金融企業で、主に住宅投資物件向けの専門的なモーゲージローンソリューションを提供しています。米国全土の独立系モーゲージブローカーと提携し、不動産投資家のニーズに合わせた短期ブリッジローンや長期賃貸物件向け融資商品を提供しています。
MLAB vs VEL — 直接比較
損益計算書 — Q3 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $65.1M | $51.6M |
| 純利益 | $3.6M | $34.8M |
| 粗利率 | 64.2% | — |
| 営業利益率 | 12.2% | 97.0% |
| 純利益率 | 5.6% | 67.3% |
| 売上前年比 | 3.6% | 32.8% |
| 純利益前年比 | 316.6% | 67.0% |
| EPS（希薄化後） | $0.65 | $0.90 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $65.1M | $51.6M | ||
| Q3 25 | $60.7M | $49.1M | ||
| Q2 25 | $59.5M | $47.6M | ||
| Q1 25 | $62.1M | $37.5M | ||
| Q4 24 | $62.8M | $38.9M | ||
| Q3 24 | $57.8M | $35.1M | ||
| Q2 24 | $58.2M | $32.4M | ||
| Q1 24 | $58.9M | $29.5M |
| Q4 25 | $3.6M | $34.8M | ||
| Q3 25 | $2.5M | $25.4M | ||
| Q2 25 | $4.7M | $26.0M | ||
| Q1 25 | $-7.1M | $18.9M | ||
| Q4 24 | $-1.7M | $20.8M | ||
| Q3 24 | $3.4M | $15.8M | ||
| Q2 24 | $3.4M | $14.8M | ||
| Q1 24 | $-254.6M | $17.3M |
| Q4 25 | 64.2% | — | ||
| Q3 25 | 61.5% | — | ||
| Q2 25 | 62.0% | — | ||
| Q1 25 | 61.8% | — | ||
| Q4 24 | 63.3% | — | ||
| Q3 24 | 61.3% | — | ||
| Q2 24 | 64.0% | — | ||
| Q1 24 | 62.1% | — |
| Q4 25 | 12.2% | 97.0% | ||
| Q3 25 | 7.8% | 72.1% | ||
| Q2 25 | 5.1% | 71.3% | ||
| Q1 25 | 2.4% | 71.7% | ||
| Q4 24 | 9.2% | 82.5% | ||
| Q3 24 | 6.1% | 60.6% | ||
| Q2 24 | 9.6% | 61.3% | ||
| Q1 24 | -460.6% | 78.8% |
| Q4 25 | 5.6% | 67.3% | ||
| Q3 25 | 4.1% | 51.7% | ||
| Q2 25 | 8.0% | 54.6% | ||
| Q1 25 | -11.4% | 50.4% | ||
| Q4 24 | -2.7% | 53.5% | ||
| Q3 24 | 5.9% | 45.1% | ||
| Q2 24 | 5.8% | 45.6% | ||
| Q1 24 | -432.2% | 58.5% |
| Q4 25 | $0.65 | $0.90 | ||
| Q3 25 | $0.45 | $0.65 | ||
| Q2 25 | $0.85 | $0.69 | ||
| Q1 25 | $-1.30 | $0.51 | ||
| Q4 24 | $-0.31 | $0.56 | ||
| Q3 24 | $0.63 | $0.44 | ||
| Q2 24 | $0.62 | $0.42 | ||
| Q1 24 | $-47.26 | $0.49 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $29.0M | $92.1M |
| 総負債低いほど良い | $68.4M | — |
| 株主資本純資産 | $186.7M | $672.5M |
| 総資産 | $434.8M | $7.4B |
| 負債/資本比率低いほどレバレッジが低い | 0.37× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $29.0M | $92.1M | ||
| Q3 25 | $20.4M | $99.0M | ||
| Q2 25 | $21.3M | $79.6M | ||
| Q1 25 | $27.3M | $51.7M | ||
| Q4 24 | $27.3M | $49.9M | ||
| Q3 24 | $24.3M | $44.1M | ||
| Q2 24 | $28.5M | $47.4M | ||
| Q1 24 | $28.2M | $34.8M |
| Q4 25 | $68.4M | — | ||
| Q3 25 | $69.4M | — | ||
| Q2 25 | $70.3M | — | ||
| Q1 25 | $71.3M | — | ||
| Q4 24 | $72.2M | — | ||
| Q3 24 | $73.1M | — | ||
| Q2 24 | $74.1M | — | ||
| Q1 24 | — | — |
| Q4 25 | $186.7M | $672.5M | ||
| Q3 25 | $178.5M | $634.3M | ||
| Q2 25 | $172.5M | $597.9M | ||
| Q1 25 | $159.8M | $563.2M | ||
| Q4 24 | $155.2M | $516.9M | ||
| Q3 24 | $161.5M | $484.6M | ||
| Q2 24 | $150.7M | $471.3M | ||
| Q1 24 | $145.4M | $452.9M |
| Q4 25 | $434.8M | $7.4B | ||
| Q3 25 | $430.4M | $7.0B | ||
| Q2 25 | $435.7M | $6.5B | ||
| Q1 25 | $433.3M | $6.0B | ||
| Q4 24 | $433.3M | $5.5B | ||
| Q3 24 | $454.1M | $5.2B | ||
| Q2 24 | $440.4M | $4.9B | ||
| Q1 24 | $446.8M | $4.6B |
| Q4 25 | 0.37× | — | ||
| Q3 25 | 0.39× | — | ||
| Q2 25 | 0.41× | — | ||
| Q1 25 | 0.45× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.49× | — | ||
| Q1 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $18.8M | $18.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $18.0M | $17.9M |
| FCFマージンFCF / 売上 | 27.7% | 34.6% |
| 設備投資強度設備投資 / 売上 | 1.1% | 0.5% |
| キャッシュ転換率営業CF / 純利益 | 5.17× | 0.52× |
| 直近12ヶ月FCF直近4四半期 | $37.9M | $40.3M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $18.8M | $18.2M | ||
| Q3 25 | $8.2M | $11.5M | ||
| Q2 25 | $1.9M | $7.7M | ||
| Q1 25 | $12.7M | $3.5M | ||
| Q4 24 | $18.1M | $37.8M | ||
| Q3 24 | $5.3M | $-17.6M | ||
| Q2 24 | $10.7M | $11.5M | ||
| Q1 24 | $12.9M | $10.6M |
| Q4 25 | $18.0M | $17.9M | ||
| Q3 25 | $7.1M | $11.4M | ||
| Q2 25 | $884.0K | $7.6M | ||
| Q1 25 | $11.9M | $3.5M | ||
| Q4 24 | $17.3M | $37.5M | ||
| Q3 24 | $3.5M | $-17.6M | ||
| Q2 24 | $9.9M | $11.4M | ||
| Q1 24 | $12.3M | $10.5M |
| Q4 25 | 27.7% | 34.6% | ||
| Q3 25 | 11.7% | 23.2% | ||
| Q2 25 | 1.5% | 15.9% | ||
| Q1 25 | 19.2% | 9.2% | ||
| Q4 24 | 27.6% | 96.4% | ||
| Q3 24 | 6.0% | -50.3% | ||
| Q2 24 | 16.9% | 35.1% | ||
| Q1 24 | 21.0% | 35.8% |
| Q4 25 | 1.1% | 0.5% | ||
| Q3 25 | 1.8% | 0.1% | ||
| Q2 25 | 1.7% | 0.2% | ||
| Q1 25 | 1.2% | 0.2% | ||
| Q4 24 | 1.3% | 0.7% | ||
| Q3 24 | 3.1% | 0.2% | ||
| Q2 24 | 1.5% | 0.3% | ||
| Q1 24 | 0.9% | 0.1% |
| Q4 25 | 5.17× | 0.52× | ||
| Q3 25 | 3.32× | 0.45× | ||
| Q2 25 | 0.40× | 0.29× | ||
| Q1 25 | — | 0.19× | ||
| Q4 24 | — | 1.81× | ||
| Q3 24 | 1.54× | -1.11× | ||
| Q2 24 | 3.17× | 0.78× | ||
| Q1 24 | — | 0.61× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
VEL
| Related Party | $19.3M | 37% |
| Nonrelated Party | $16.9M | 33% |
| Other | $15.4M | 30% |
